ArticleThe Journal of experimental medicine1997
Mapping the active site of CD59.
Article in The Journal of experimental medicine, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- A specific and sensitive assay for blood levels of glycated CD59: a novel biomarker for diabetes.American journal of hematology · 2013Trial
- Glycated CD59: a novel biomarker for gestational diabetes.Endocrine reviews · 2026Review
- Intracellular complement: Evidence, definitions, controversies, and solutions.Immunological reviews · 2023Review
- Molecular Pathogenesis of Endotheliopathy and Endotheliopathic Syndromes, Leading to Inflammation and Microthrombosis, and Various Hemostatic Clinical Phenotypes Based on "Two-Activation Theory of the Endothelium" and "Two-Path Unifying Theory" of Hemostasis.Medicina (Kaunas, Lithuania) · 2022Review
- Bispecific mAbInternational journal of molecular sciences · 2022Article
- Intermedilysin cytolytic activity depends on heparan sulfates and membrane composition.PLoS genetics · 2021Article
- Plasma glycated CD59 (gCD59), a novel biomarker for the diagnosis, management and follow up of women with Gestational Diabetes (GDM) - protocol for prospective cohort study.BMC pregnancy and childbirth · 2020Article
- A distinctive histidine residue is essential for in vivo glycation-inactivation of human CD59 transgenically expressed in mice erythrocytes: Implications for human diabetes complications.American journal of hematology · 2017Article
- Role of complement and complement regulatory proteins in the complications of diabetes.Endocrine reviews · 2015Review
- The cytolytic activity of vaginolysin strictly depends on cholesterol and is potentiated by human CD59.Toxins · 2015Article
- Mapping the intermedilysin-human CD59 receptor interface reveals a deep correspondence with the binding site on CD59 for complement binding proteins C8alpha and C9.The Journal of biological chemistry · 2011Article
- Modulation of protective T cell immunity by complement inhibitor expression on tumor cells.Cancer research · 2008Article
- Transcriptional control of complement receptor gene expression.Immunologic research · 2007Review
- Glycation of CD59 impairs complement regulation on erythrocytes from diabetic subjects.Immunology · 2005Article
- Article
- CD59 blocks not only the insertion of C9 into MAC but inhibits ion channel formation by homologous C5b-8 as well as C5b-9.The Journal of physiology · 2002Article
- Molecular basis for a link between complement and the vascular complications of diabetes.Proceedings of the National Academy of Sciences of the United States of America · 2000Article
- Surface antigen expression and complement susceptibility of differentiated neuroblastoma clones.The American journal of pathology · 2000Article
- Production and functional characterization of a soluble recombinant form of mouse CD59.Immunology · 2000Article
- Targeting of functional antibody-CD59 fusion proteins to a cell surface.The Journal of clinical investigation · 1999Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
CD59 is a widely distributed membrane-bound inhibitor of the cytolytic membrane attack complex (MAC) of complement. This small (77 amino acid) glycoprotein is a member of the Ly6 superfamily of proteins and is important in protecting host cells from the lytic and proinflammatory activity of the MAC. CD59 functions by binding to C8 and/or C9 in the nascent MAC and interfering with C9 membrane insertion and polymerization. We present data obtained from a combination of molecular modeling and mutagenesis techniques, which together indicate that the active site of CD59 is located in the vicinity of a hydrophobic groove on the face of the molecule opposite to a "hydrophobic strip" suggested earlier. In addition, removal of the single N-linked glycosylation site at Asn18 of CD59 resulted in an enhancement of complement inhibitory activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.